Skip to main content

Advertisement

SpringerLink
Log in

Reply to a letter to the editor: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial

  • Letter to the Editor (by invitation)
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Călugăru D, Călugăru M (2016) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. [in press]

  2. Eter N, Mohr A, Wachtlin J et al (2016) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-016-3431-x

    PubMed Central  Google Scholar 

  3. Querques L, Querques G, Lattanzio R et al (2013) Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica 229:21–25. doi:10.1159/000342160

    Article  CAS  PubMed  Google Scholar 

  4. Coscas G, Augustin A, Bandello F et al (2014) Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24:1–9. doi:10.5301/ejo.5000376

    Article  PubMed  Google Scholar 

  5. Augustin AJ, Holz FG, Haritoglou C et al (2015) Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica 233:18–26. doi:10.1159/000368840

    Article  CAS  PubMed  Google Scholar 

  6. Singer MA, Capone A Jr, Dugel PU et al (2015) Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol 15:33. doi:10.1186/s12886-015-0018-y

    Article  PubMed  PubMed Central  Google Scholar 

  7. Deobhakta A, Chang LK (2013) Inflammation in retinal vein occlusion. Int J Inflamm 2013:438412. doi:10.1155/2013/438412

    Article  Google Scholar 

  8. Yeh WS, Haller JA, Lanzetta P et al (2012) Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 119:1190–1198. doi:10.1016/j.ophtha.2011.12.028

    Article  PubMed  Google Scholar 

  9. Korobelnik JF, Kodjikian L, Delcourt C et al (2016) Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 254(12):2307–2318. doi:10.1007/s00417-016-3394-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Münster Medical School, Münster, Germany

    Nicole Eter

  2. Eye Hospital St. Joseph-Stift, Bremen, Germany

    Andreas Mohr

  3. Augenabteilung, Sankt Gertrauden Krankenhaus, Berlin, Germany

    Joachim Wachtlin

  4. University Eye Care Hospital, Göttingen, Germany

    Nicolas Feltgen

Authors
  1. Nicole Eter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Mohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joachim Wachtlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicolas Feltgen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicole Eter.

Ethics declarations

Conflict of interest

The study was sponsored by Allergan plc, Dublin, Ireland. Nicole Eter is a consultant to and has received research support and honoraria and travel expenses from Bayer, Novartis, and Roche, and has received honoraria and travel expenses from Alimera, Allergan, and Heidelberg Engineering. Andreas Mohr has received a research grant and travel reimbursement from DORC, lecture fees from Alcon, Allergan, and AMO, and lecture fees and travel reimbursement from Bayer Healthcare and Novartis. Joachim Wachtlin has received speaker fees from Allergan. Nicolas Feltgen is a consultant to and has received honoraria and travel expenses from Allergan, Bayer HealthCare, and Novartis Pharma GmbH. The authors have full control of all primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eter, N., Mohr, A., Wachtlin, J. et al. Reply to a letter to the editor: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 255, 429–430 (2017). https://doi.org/10.1007/s00417-016-3560-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-016-3560-2

Keywords

Search

Navigation